GlassScriptPhysician profile
Neil Billeaud
NPI 1811158637
$1,073.33
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $581 · 2020: $429 · 2021: $63.09.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $312.73 | 2019-2020 | |
| Ucb, INC. | $270.47 | 2019-2020 | |
| Sk Life Science, INC. | $146.91 | 2020 | |
| Lilly USA, LLC | $68.09 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $48.71 | 2020 | |
| Amgen INC. | $40.64 | 2019 | |
| Abbvie INC. | $33.27 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $29.82 | 2021 | |
| Eisai INC. | $20.74 | 2020 | |
| Emd Serono, INC. | $19.77 | 2020 | |
| Novartis Pharmaceuticals Corporation | $19.65 | 2019 | |
| Greenwich Biosciences, INC. | $18.94 | 2019 | |
| Livanova USA, INC. | $17.63 | 2019 | |
| Aprecia Pharmaceuticals, LLC | $14.51 | 2020 | |
| Neurelis, INC. | $11.45 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Billeaud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.